➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Tartaric acid

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Tartaric acid?

Tartaric acid is an investigational drug.

There have been 9 clinical trials for Tartaric acid. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2019.

The most common disease conditions in clinical trials are Lymphoma, B-Cell, Venous Thromboembolism, and Lymphoma. The leading clinical trial sponsors are Boehringer Ingelheim, Shiraz University of Medical Sciences, and Mirati Therapeutics Inc.

There are two hundred and seventy-nine US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Tartaric acid
A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy VolunteersPopulation Health Research InstitutePhase 4
This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are ToleratedBoehringer IngelheimPhase 1
The Effects of Rhus Coriaria L. on Serum Uric Acid LevelsShiraz University of Medical SciencesN/A

See all Tartaric acid clinical trials

Clinical Trial Summary for Tartaric acid

Top disease conditions for Tartaric acid
Top clinical trial sponsors for Tartaric acid

See all Tartaric acid clinical trials

US Patents for Tartaric acid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tartaric acid   Get Started Free Salts of ranitidine and complexes of bismuth with carboxylic acids, and pharmaceutical compositions thereof Glaxo Group Limited (GB2)   Get Started Free
Tartaric acid   Get Started Free Intermediates for the synthesis of benzoxazol- and benzothiazolamine derivatives, useful as anti-anoxic agents Janssen Pharmaceutica N.V. (Beerse, BE)   Get Started Free
Tartaric acid   Get Started Free 6-(substituted)methylenepenicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof Pfizer Inc. (New York, NY)   Get Started Free
Tartaric acid   Get Started Free Organic compounds and their pharmaceutical use Lilly Industries Limited (Basingstoke, GB2)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tartaric acid

Drugname Country Document Number Estimated Expiration Related US Patent
Tartaric acid Austria AT398200 2008-07-18   Get Started Free
Tartaric acid Austria ATA172889 2008-07-18   Get Started Free
Tartaric acid Australia AU3817889 2008-07-18   Get Started Free
Tartaric acid Australia AU632052 2008-07-18   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.